You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心脈醫療(688016.SH):成功獲得第二十五屆中國專利金獎

格隆匯6月8日丨心脈醫療(688016.SH)公佈,根據《國家知識產權局關於第二十五屆中國專利獎授獎的決定》(國知發運字〔2025〕20號),上海微創心脈醫療科技(集團)股份有限公司(以下簡稱"公司"或"心脈醫療")成功獲得第二十五屆中國專利金獎。

中國專利獎由國家知識產權局與世界知識產權組織共同評選,旨在引導和推進知識產權工作對供給側結構性改革、創新型國家建設、經濟高質量發展發揮重要作用;鼓勵和表彰專利權人和發明人(設計人)對技術(設計)創新及經濟社會發展作出的突出貢獻。根據《中國專利獎評獎辦法》規定,中國專利獎參評項目採用推薦方式,由地方知識產權局、國務院有關部門和單位知識產權工作管理機構、全國性行業協會、中國科學院院士和中國工程院院士等根據當年評選通知要求擇優推薦。第二十五屆中國專利獎共授獎中國專利金獎30項,中國外觀設計金獎10項,中國專利銀獎60項,中國外觀設計銀獎15項,中國專利優秀獎607項,中國外觀設計優秀獎47項。心脈醫療此次獲得中國專利金獎,是對公司多年堅持創新、深耕知識產權領域的權威認可。

公司自成立以來,一直深耕於主動脈及外周血管介入醫療器械領域,通過多年的經驗積累,已發展成我國主動脈血管介入醫療器械的龍頭企業。截至2024年12月31日,公司累計提交專利申請724項,累計已授權的境內外專利合計242項,其中境內授權專利155項(包括髮明專利74項、實用新型專利77項、外觀設計專利4項),境外授權專利87項(均爲發明專利)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account